Immunoglobulin chimeric monomer-dimer hybrids

  • US 7,348,004 B2
  • Filed: 01/05/2005
  • Issued: 03/25/2008
  • Est. Priority Date: 05/06/2003
  • Status: Active Grant
First Claim
Patent Images

1. A method of treating a subject with a disease or condition comprising administering a pharmaceutically effective amount of a monomer-dimer hybrid immunoconjugate to the subject, wherein the immunoconjugate comprises
X-La-F1:

  • F2 or F2;

    F1-La-X,wherein;

    X is a single biologically active molecule capable of treating the disease or condition;

    L is a linker;

    a is any integer or zero;

    ;

    represents a chemical association;

    F1 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site and does not comprise a biologically active molecule,F2 is at least a portion of an immunoglobulin constant region comprising an FcRn binding site; and

    does not comprise a biologically active molecule or immunoglobulin variable region.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×